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A B S T R A C TObjectives: Gene-expression profiling (GEP) reliably supplements tra-
ditional clinicopathological information on the tissue of origin (TOO)
in metastatic or poorly differentiated cancer. A cost-effectiveness
analysis of GEP TOO testing versus usual care was conducted from a
US third-party payer perspective. Methods: Data on recommendation
changes for chemotherapy, surgery, radiation therapy, blood tests,
imaging investigations, and hospice care were obtained from a retro-
spective, observational study of patients whose physicians received
GEP TOO test results. The effects of chemotherapy recommendation
changes on survival were based on the results of trials cited in
National Comprehensive Cancer Network and UpToDate guidelines.
Drug and administration costs were based on average doses reported
in National Comprehensive Cancer Network guidelines. Other unit
costs came from Centers for Medicare & Medicaid Services fee
schedules. Quality-of-life weights were obtained from literature. Boot-
strap analysis estimated sample variability; probabilistic sensitivity
analysis addressed parameter uncertainty. Results: Chemotherapysee front matter Copyright & 2013, International
r Inc.
.1016/j.jval.2012.09.005
nford.edu.
pondence to: John Hornberger, Cedar Associates, 37regimen recommendations consistent with guidelines for final
tumor-site diagnoses increased significantly from 42% to 65% (net
difference 23%; Po 0.001). Projected overall survival increased from
15.9 to 19.5 months (mean difference 3.6 months; two-sided 95%
confidence interval [CI] 3.2–3.9). The average increase in quality-
adjusted life-months was 2.7 months (95% CI 1.5–4.3), and average
third-party payer costs per patient increased by $10,360 (95% CI
$2,982–$19,192). The cost per quality-adjusted life-year gained was
$46,858 (95% CI $13,351–$104,269). Conclusions: GEP TOO testing
significantly altered clinical practice patterns and is projected to
increase overall survival, quality-adjusted life-years, and costs, result-
ing in an expected cost per quality-adjusted life-year of less than
$50,000.
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More than 30,000 cases of cancer of unknown primary (CUP) are
diagnosed annually in the United States, representing 2% of all new
cancer cases [1,2]. In other cases, a leading diagnosis for the
primary site has been made; however, substantial uncertainty
about the tissue-site diagnosis still remains, especially when the
cancer is metastatic, poorly differentiated, or undifferentiated. This
can result in an exhaustive and costly ‘‘diagnostic odyssey’’ [3,4].
Current National Comprehensive Cancer Network (NCCN)
guideline–recommended regimens for CUP consist of paclitaxel
and carboplatin with or without etoposide, docetaxel and carbo-
platin, gemcitabine and cisplatin, or gemcitabine and docetaxel;
median survival with these treatments is 6 to 9 months [5,6].
Studies have shown that survival may be improved if cancer-
specific therapy is targeted to the correct tumor type, demon-
strating the need for effective and accurate identification of the
tissue of origin (TOO) [5,7,8].
The NCCN guideline–recommended evaluation of metastatic
or poorly differentiated CUP includes a thorough history and
physical examination (including breast, genitourinary, pelvic, andrectal examinations where appropriate), complete blood cell
count, urinalysis, basic serum chemistries, chest radiograph,
and computed tomography or magnetic resonance imaging of
the abdomen and pelvis [5]. Immunohistochemistry (IHC) testing
of the biopsy material is commonly used to characterize cellular
differentiation and pathological diagnosis in poorly differentiated
carcinomas [5]. Studies have recognized limitations—for exam-
ple, with respect to consistency, reproducibility, sensitivity, spe-
cificity, and result interpretation or reporting—of conventional
morphological evaluation and IHC testing, prompting a search for
more reliable and accurate methods of identifying the primary
site in poorly differentiated carcinomas [9–12].
The gene-expression profiling (GEP) TOO Test (Pathwork Diag-
nostics, Inc., Redwood City, CA) of biopsy material has been
cleared by the US Food and Drug Administration and validated to
provide independent information on the TOO [13–16]. The pro-
cessing laboratory has Clinical Laboratory Improvement Amend-
ments certification. The GEP TOO test is a microarray, reagent,
and analytics kit that uses a 2000-gene profile to quantify the
similarity of tumor specimens to 15 cancer types representing 58
morphologies. GEP TOO test results provide similarity scores thatSociety for Pharmacoeconomics and Outcomes Research (ISPOR).
15 Haven Avenue, Suite 100, Menlo Park, CA 94025, USA.
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among a panel of 15 tissue types. The probability of obtaining a
true positive tissue call with a similarity score of 30 or more is
92.9% (95% confidence interval [CI] 90.3–95.0), and the probability
of obtaining a true negative tissue call with a similarity score of 5
or less is 99.7% (95% CI 99.6–99.8) [16]. In a clinical verification
study, Dumur et al. [17] showed higher performance of the GEP
TOO test to identify the correct tissue site compared with well-
established immunohistochemical algorithms. In a subsequent
clinical-utility study of 107 patients with CUP, physicians changed
the primary tissue-site diagnosis in 50% of the patients (95% CI
43–58) and changed cancer-specific management in 65% of the
patients (95% CI 58–73) [18].
Although the long-term clinical and economic implications of
GEP TOO testing are yet to be assessed, several studies have
shown that adherence to guideline-recommended treatment
may result in more cost-effective management of patients with
cancer [19–21]. The specific aim of our study was to assess the
cost-effectiveness of GEP TOO testing in the context of the
current diagnostic paradigm and standard treatment regimens.Methods
Analytical Framework
We performed a cost-effectiveness analysis from a US third-
party payer perspective to assess the effect of GEP TOO testing
on quality-adjusted life-years (QALYs) and direct medical
costs
over a patient’s lifetime. We performed the analysis with an
individual-sampling method by using data from a retrospec-
tive, observational study of patients whose physician had
received the GEP TOO test results to help diagnose the tissue
site of a patient’s malignancy and guide appropriate therapy.
The study included 107 patients whose physicians ordered and
received a GEP TOO test result between July 2009 and Decem-
ber 2009. Patients were 18 years or older and had metastatic
cancer in which the primary origin remained uncertain
despite extensive clinical and pathological evaluation. The
study documented changes in tumor-site diagnosis and cancerFig. 1 – 1Based only on history/physical examination, imaging
examination, imaging studies, pathology, and GEP TOO results;
final reported tissue-site diagnosis after receiving GEP TOO resu
chemotherapy; GCR, guideline-consistent regimen; BSC, best-sumanagement recommendations before and after physicians
received the GEP TOO test results. An institutional review
board approved all aspects of the study (Quorum Review, Inc.,
Seattle, WA).
We defined usual care as cancer management decisions based
on history and physical examination, imaging studies, selected
blood tests, and pathology, including IHC (Fig. 1). With usual care,
the physician selected a treatment without the benefit of diag-
nostic information from the GEP TOO test.
Before and after receiving the GEP TOO test results, some
physicians in the study recommended a chemotherapy regimen.
We refer to chemotherapy regimens that included one or more
agents recommended by clinical guidelines as guideline-consistent
regimens (GCRs). We refer to regimens containing no agents recom-
mended by clinical guidelines as non-GCRs. Two independent
researchers determined whether to classify each chemotherapy
regimen as a GCR or non-GCR on the basis of the regimens
recommended in NCCN and UpToDate guidelines for metastatic
and/or poorly differentiated cancers, and according to the physi-
cian’s final tissue-site diagnosis [5,22]. The two independent
researchers reached the same conclusions about whether regimens
were GCRs or non-GCRs for 207 of the 214 chemotherapy regimens
recommended in this study; consensus was reached on 213 total
cases. The uncertain regimen was a pre-GEP TOO treatment recom-
mendation for gemcitabine and docetaxel in a patient with an initial
diagnosis of CUP. After GEP TOO testing, the patient’s diagnosis
changed to soft tissue sarcoma and the chemotherapy treatment
recommendation changed to doxorubicin and cisplatin. A third
independent rater determined that the pre-GEP TOO chemotherapy
recommendation was a GCR for soft tissue sarcoma and reviewed
and confirmed the other six classifications on which the two other
independent raters had initially disagreed.
We calculated the incremental cost per QALY gained as the ratio
of the difference in lifetime costs of care and QALYs gained when
physicians determined the final tissue-site diagnosis after obtaining
GEP TOO test results versus before obtaining results, that is, ‘‘usual
care’’ [23]. We computed QALYs as the product of quality-of-life
(QOL) weights and literature-derived survival time. We report costs
in 2011 US dollars. The model applied a standard annual discount
rate of 3% for costs and benefits [23,24]. The time horizon equaled
the patient’s lifetime [23].studies, and pathology; 2based on history/physical
3whether CT is GCR versus non-GCR is based on physician’s
lts. GEP, gene-expression profiling; TOO, tissue of origin; CT,
pportive care.
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We reviewed the medical literature to document median overall
survival associated with chemotherapy regimens for specific
tumor types, relying primarily on estimates from controlled trials
or meta-analyses of controlled trials cited in UpToDate or NCCN
guidelines [5,22]. We abstracted studies initially for information
on patient survival when patients with metastatic tumors had
received no chemotherapy regimen; in most instances, these
estimates reflected the survival of patients in a placebo-control
arm of a trial. For studies of GCRs, we abstracted estimates of the
median overall survival from published studies. Estimates of the
survival effects of chemotherapy regimens that are not recom-
mended in guidelines for a tissue type were often unavailable in
the literature. In the base case, we assumed that non-GCRs not
provided in the literature had the same effect on survival as those
found in the literature and we varied the effect on survival
between 0% (no survival benefit over best supportive care) and
100% (same benefit as GCRs). The survival benefit associated with
GCR versus non-GCR varies by tissue type (Table 1). For example,
no benefit has been reported for patients with neuroendocrine
pancreatic cancer. The maximum benefit between GCR and non-
GCR is 24 months, reported for ovarian cancer.Table 1 – Median overall survival by tissue-type diagnosis and
Median overa
Physician’s final tissue type
diagnosis [Reference]
No
CT,
BSC
Non-
GCR
CT
GCR
CT p
Anal [25] 1.0 11.0 12.0
Bladder [26–28] 4.6 9.5 13.6
Breast [29–35] 13.0 16.9 25.2
Cervical [36] 5.8 6.1 6.6
Cholangiocarcinoma [37–39] 2.5 5.2 10.8
Colorectal [40–48] 5.5 10.9 21.6
Extragonadal germ cell [49,50] no
data
449 4120
Gastric [51–53] 3.1 9.0 9.9
Head and neck [54–56] 4.0 4.9 6.9
Kidney [57–60] 4.5 9.9 21.2
Liver [61–64] 4.2 6.8 9.2
Lung [65–70] 5.3 6.7 9.7
Melanoma [71,72] 5.8 7.5 11.0
Ovarian [73–76] 6.0 8.1 32.0
Pancreas [77–84] 3.4 5.1 8.5
Pancreatic neuroendocrine
[78,85]
44.0 44.0 44.0
Pancreatobiliary [37,39] 2.5 4.9 9.9
Parotid gland [86,87] 4.0 11.0 15.0
Sarcoma [88–91] 7.2 8.0 12.2
Unknown [92–95] 4.5 6.9 8.9
Urethral [96,97] 5.8 7.9 22.0
Urothelial [26,98,99] 6.0 7.7 11.2
Uterine [100] 5.8 6.7 8.6
Weighted median survival 6.2 8.5 14.7
Note. CT benefit calculated by averaging the expected OS gain (based on
BSC, best-supportive care; CT, chemotherapy; GCR, guideline-consis
recommended treatments for the cancer type; GEP, gene-expression pro
OS for patients with non-guideline–recommended treatments for the ca
the stated cancer type; Patients (%), percentage of the total patient popula
average OS for treatments prescribed before GEP TOO testing; Post-GEP T
GEP TOO testing; TOO, tissue of origin.
* OS of 5.8 mo imputed for BSC where no literature could be found.We conservatively assumed that changes in surgery and
radiation therapy associated with receiving GEP TOO test results
had no effect on overall survival; this assumption biases the
analyses against GEP TOO testing. Early referral to hospice care
has been shown to increase the overall survival by approximately
2.7 months; we therefore ascribed a 2.7-month survival benefit
for patients referred to hospice [101,102]. Some patients who
were referred to hospice after GEP TOO testing also received
chemotherapy, presumably for palliative purposes. We set the
effect of these management changes on overall survival to be
equal to the maximum of the effect from either the recom-
mended chemotherapy or hospice care, but not both. We
obtained de-identified social security data on whether each
patient had died and the date of death. We used these data to
calculate the duration of survival from the time that physicians
received the test results.
We assigned QOL weights on the basis of the classification of
the chemotherapy regimen (no chemotherapy, non-GCR, or GCR).
We searched the online Tufts Cost-Effectiveness Analysis Registry
database and PubMed for evidence on QOL weights for metastatic
cancer and the effect of chemotherapy on response and
chemotherapy-related adverse events [101,102]. We limited the
search to controlled trials and used ‘‘metastatic’’ and the nameschemotherapy regimen.
ll survival for advanced-stage cancer (mo)
Pre-GEP TOO
rescribed CT
Post-GEP TOO
prescribed CT
Patients
(n)
Patients
(%)
1.0 11.0 1 1
9.5 11.6 2 2
16.3 18.9 8 7
6.6 6.6 1 1
10.8 10.8 3 3
14.3 19.7 12 11
449 449 1 1
9.0 9.9 2 2
4.9 6.9 3 3
12.3 26.0 3 3
6.8 9.1 4 4
7.5 7.4 14 13
11.0 11.0 2 2
23.8 29.7 9 8
4.9 8.4 10 9
44.0 44.0 1 1
9.9 9.9 2 2
11.0 13.7 1 1
9.3 12.5 6 6
6.9 6.6 17 16
7.9 7.9 1 1
9.8 10.9 3 3
8.6 8.6 1 1
11.1 13.6 107 100
response to actual prescribed CT) of all cases of each cancer type.
tent regimen; GCR CT, average OS for patients with guideline-
filing; No CT, BSC, OS for BSC or no treatment; Non-GCR CT, average
ncer type; OS, overall survival; Patients (n), number of patients with
tion with the stated cancer type; Pre-GEP TOO prescribed treatment,
OO prescribed treatment, average OS for treatments prescribed after
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‘‘EQ-5D’’) as search terms. QOL weights associated with meta-
static cancer were highly variable across studies, ranging from
0.15 to 0.8. In a study of metastatic renal cell carcinoma, the
initial best supportive care QOL weight was 0.5509, which
increased to 0.7153 for non-GCR (interferon-a) chemotherapy
and to 0.7599 with use of a targeted chemotherapy regimen
(sunitinib) that is consistent with NCCN guidelines [103]. For
adverse events and/or inconvenience related to the chemother-
apy regimen, we added a 0.0386 decrement (or tariff) in QOL,
multiplied by an average of 4 months of receiving a chemother-
apy regimen [103]. Because studies have not reported QOL
weights associated with referrals to hospice care, we ascribed
no change in QOL to referrals to hospice care. We also ascribed
no changes in QOL to reductions in patient uncertainty about
their tissue-site diagnosis and management plans [104]. Omit-
ting QOL effects for hospice and uncertainty of diagnosis
probably biased the analysis against GEP TOO testing. We also
ascribed no QOL change to the use of radiation therapy
because of a lack of published data. The effects of radiation
therapy on QOL are complex because QOL might decline
because of radiation-related adverse effects, but it might
also increase as a result of tumor debulking and symptom
management. Presumably, physicians and patients considered
these trade-offs, and so the benefits of tumor debulking
and symptom management outweighed the risk of adverse
effects.Costs
We estimated third-party costs per patient for all chemother-
apy regimens, radiation therapies, surgeries, hospice care,
further investigations, and IHCs prescribed for each patient.
The GEP TOO test kit’s cost used for these analyses was the list
price of $4400. We assumed that GEP TOO testing would not
affect surgeries for diagnosis, staging, and debulking that had
been performed before physicians received the test results. We
included only new investigations arising from the GEP TOO
test results in the analyses. We derived unit drug costs from
Centers for Medicare & Medicaid Services (CMS) fee schedules,
and we based dosages on NCCN guidelines, package inserts,
UpToDate.com, and OVID Clin-eguideTM [18,22,105,106]. We
derived drug administration costs from the number of hours
to infuse agents and the CMS reimbursement associated
with outpatient infusion Current Procedural Terminology
codes [105].
We applied CMS Medicare Severity Diagnosis-Related Group
weights to calculate the costs of surgeries and radiation therapy
[106] and CMS fee schedules for costs of IHCs (HCPC 88342) [107].
We searched the literature for the percentage change in third-
party payer costs associated with referrals to hospice care
[19,108–110]. Studies reported a mean reduction of between 11%
and 79% in third-party payer costs for each referral to hospice
care. The average reduction in third-party payer costs for hospice
care referrals, weighted by study size, was 46%, which amounted
to a $6520 savings for hospice care referrals that we included in
the model. We omitted costs related to outpatient visits because
patients in the target population are seen frequently for surveil-
lance purposes, and GEP TOO testing is unlikely to alter these
patterns of care significantly. We hypothesized that the admin-
istration of more effective chemotherapy regimens delays dis-
ease progression and thereby reduce morbidity. Our model
conservatively omitted these costs, and so only the immediate
effects of GEP TOO testing on changes in clinical practice,
medical resource use, and thus third-party payer costs are
considered.Data Analysis and Sensitivity Analysis
The primary end points for our data analysis were (1) mean
change in overall survival, (2) mean change in QALYs, (3) mean
change in total cancer-related costs, and (4) cost per QALY gained
before and after GEP TOO testing. We summarized study vari-
ables by using descriptive statistics: sample means, medians,
SDs, minimums, and maximums. We converted overall survival
medians from the literature to means for the QALY analysis by
modeling survival with constant hazard ratios, which showed
median survival to be 70% of mean survival. We used a two-sided
bootstrap t test at a 0.05 level of significance to assess the effect
of sample variance on differences in end points before and after
GEP TOO testing [111,112].
We conducted a one-way sensitivity analysis, a two-way
sensitivity analysis, and a probabilistic sensitivity analysis on
the model parameters by using a second-order Monte Carlo
simulation (computational algorithm based on repeated random
sampling). We estimated the sample variance in QALYs by using
bootstrap techniques; we assessed 95% CIs in QALYs and cost per
QALY due to parameter uncertainty, such as utilities, in the
probabilistic sensitivity analysis. We introduced the variable
‘‘relative effect of GEP TOO testing’’ to address the limitations of
an observational design. In sensitivity analyses, this variable
modified the relative effect of GEP TOO testing from the observed
effects seen in the study. Table 2 shows the input parameters and
distributions used in the model.Results
The characteristics of patients in the study are shown in Table 3;
further details are given in Appendix Table 1 found at doi:
10.1016/j.jval.2010.10.016. Sixty-one (57%) patients were women.
The mean patient age was 6412 years; 54 (50%) patients were 65
years or older. Reported race/ethnicity was white for 89% of the
patients. Of the 91 patients with a reported Easter Cooperative
Oncology Group score, 87 (81%) had a score of 2 or less. A total of
19 biopsy sites were reported in the tissue samples submitted for
GEP TOO testing. The six most common biopsy sites, each with at
least five reported cases, were lymph node (21%), soft tissue
(20%), liver (18%), lung (9%), bone (7%), and brain (5%). The most
common diagnoses after GEP TOO testing, each with at least nine
reported cases, were lung (13%), colorectal (11%), pancreas (9%),
and ovarian (8%) cancer.
Table 1 shows the median overall survival by tissue-type
diagnosis and chemotherapy regimen. With best supportive care
involving no chemotherapy, the median overall survival across all
tissue-type diagnosis is projected to be 6.2 months (range 1–44
months). Median overall survival using a non-GCR regimen (i.e., a
regimen that is not guideline consistent for the final tissue-type
diagnosis) increases to 8.9 months (range 4.9 to at least 49
months). Median overall survival using a GCR regimen that is
specific for the final tissue-type diagnosis increases to 15.9
months (range 6.6 to at least 120 months). Patients with meta-
static cancers such as breast, colorectal, kidney, ovarian, and
pancreatobiliary survive substantially longer after undergoing
GCR than after non-GCR. In contrast, studies showed that
patients with anal, cervical, gastric, and uterine metastatic
cancers would receive only a small or insignificant benefit from
GCR. Based on the regimen recommended before GEP TOO
testing, the median overall survival is estimated to be 11.1
months (range 1 to at least 49 months).
GEP TOO testing resulted in a significant change in recom-
mended chemotherapy regimens (Table 4). Before having infor-
mation from GEP TOO testing, physicians recommended GCRs
for 42% of the patients and non-GCRs for 28% of the patients.
Table 2 – Parameters and distributions.
Parameter Base case SD Distribution Alpha/shape Beta/shape
Costs ($)
Per patient without GEP TOO testing
Chemotherapy 10,426 1,678 Gamma 39 270
Administration 3,379 518 Gamma 43 79
IHC 1,190 61 Gamma 381 3
Radiation therapy 1,476 193 Gamma 58 25
Surgeries 0 171 Gamma 0 292,410,000
Further investigation 0 10 Gamma 0 1,000,000
Hospice 0 214 Gamma 0 45,796,000
Per patient with GEP TOO testing
Chemotherapy 17,255 3,451 Gamma 25 690
Administration 3,569 714 Gamma 25 143
IHC 1,190 61 Gamma 381 3
Radiation therapy 777 157 Gamma 24 32
Surgeries 461 171 Gamma 7 63
Further investigation 32 10 Gamma 9 3
Hospice 853 214 Gamma 16 54
Other resources and costs
Cost per IHC test 120 6 Gamma 400 0
Cost per radiation therapy course 4,156 540 Gamma 59 70
Percent savings with hospice 40% 4% 4% Beta 60 92
Survival
QALM — sample variance 1.00 0.20 Log-normal — —
Survival with hospice (mo) 2.70 0.20 Normal — —
Duration of chemotherapy (mo) 4.00 0.10 Normal — —
Effect of other regimens on survival 32% 3% Beta 78 164
Relative effect of GEP TOO testing 1.00 0.05 Normal — —
Utilities
No CT, BSC 0.55 0.06 Beta 44 36
Non-GCR 0.72 0.07 Beta 28 11
GCR 0.76 0.08 Beta 23 7
Adverse event tariff, non-GCR 0.04 0.00 Beta 96 2392
Adverse event tariff, GCR 0.04 0.00 Beta 96 2392
BSC, best supportive care; CT, chemotherapy; GCR, guideline-consistent regimen; GEP, gene expression profiling; IHC, immunohistochemistry;
OS, overall survival; QALM, quality-adjusted life-month; TOO, tissue of origin test.
Table 3 – Patient characteristics.
Characteristic Number (%), or
mean  SD
Number of patients 107
Sex: Female 61 (57)
Age (y)
All, mean  SD 64  12
Age 65 y and older 54 (50)
Race/ethnicity
White 95 (89)
African American 4 (4)
Hispanic, Latino, or Spanish heritage 4 (4)
Asian American 2 (2)
Other 2 (2)
Performance status (ECOG)
0 31 (29)
1 35 (33)
2 21 (20)
3 4 (4)
Not reported 16 (15)
ECOG, Eastern Cooperative Oncology Group.
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patients before obtaining GEP TOO test results. With the addi-
tional information from GEP TOO testing, physicians recom-
mended a GCR for 23% more patients, an increase from 42% to
65% of the patients, and they recommended a non-GCR for 15%
fewer patients, a decline from 28% to 13%. GEP TOO testing also
increased the proportion of patients whose physicians recom-
mended chemotherapy from 70% to 79%. Other aspects of cancer
management that changed after GEP TOO testing were that
physicians recommended additional investigations (blood tests
or imaging) for 18 (17%) patients, referring 14 patients to hospice
immediately after receiving GEP TOO test results, recommending
radiation therapy for 19 fewer patients and additional surgery for
5 patients.
The median overall survival projected for patients after GCR was
13.6 (range 6.6 to at least 49 months) (Table 1). The actual median
overall survival for the 107 patients in the cohort was 14.0 months
(95% CI 10.2–18.6) (Appendix Figure 1 found at doi: 10.1016/
j.jval.2010.10.016). The estimate of median overall survival based
on the literature cited in NCCN guidelines is thus well calibrated
with actual survival of patients enrolled in the cohort study. These
median survival values correspond to GEP TOO increasing the mean
overall survival by 3.55 months (95% CI 3.17–3.91) to 19.46 months
Table 4 – Change in chemotherapy.
Usual care GEP TOO testing Total
GCR CT Non-GCR CT No CT, BSC
GCR CT 38 0 7 45 (42%)
Non-GCR CT 19 9 2 30 (28%)
No CT, BSC 13 5 14 32 (30%)
Total 70 (65%) 14 (13%) 23 (21%) 107 (100%)
Note. Pearson chi-square ¼ 28.6; Po 0.001.
BSC, best supportive care; CT, chemotherapy; GCR, guideline-consistent regimen; GEP, gene-expression profiling; TOO, tissue of origin.
VA L U E I N H E A LT H 1 6 ( 2 0 1 3 ) 4 6 – 5 6 51(Table 5). Correspondingly, quality-adjusted survival increased by
2.65 months after GEP TOO test results (95% CI 1.50—4.28).
The per-patient cost of recommended chemotherapy drugs
and administration increased from $13,805 with usual care to
$20,825 after GEP TOO testing (Table 5). Average costs per patient
after GEP TOO test results increased for recommended che-
motherapies, surgeries, and new blood tests and imaging inves-
tigations, whereas costs per patient decreased for recommended
radiation therapy and hospice care. Average costs per patient
related to the recommended immediate changes in cancer care
increased from $16,471 to $26,831, including $4400 for the cost
of the GEP TOO test kit. The net difference in cost per patient
was $10,360 (95% CI $2,982–$19,192). We estimated the incre-
mental cost-effectiveness ratio (ICER) to be $46,858 (95% CI
$13,351–$104,269) (Table 5).
By considering parameter uncertainty and sample variance in
the probabilistic sensitivity analysis, the 2.5th and 97.5th percen-
tiles of QALYs were 0.125 and 0.360, respectively; the 2.5th andTable 5 – Base-case results.
Outcomes Usual care
Mean SE M
Appropriateness of CT
No CT, BSC 29.9% 2
Non-GCR CT 28.0% 1
GCR CT 42.1% 6
Mean overall survival, months
Unadjusted 15.90 (1.27) 1
Adjusted* 10.64 (0.91) 1
Costs per patient (2011 USD)
Chemotherapy
Drugs $10,426 ($1,678) $1
Administration $3,379 ($518) $
Immunohistochemistryz $1,190 ($61) $
Radiation therapy $1,476 ($193) $
Surgeriesy — — $
Further investigations** — —
Referral to hospice care — — 
GEP TOO test — — $
Total $16,471 ($1,895) $2
Cost per QALY (2011
Abbreviations: BSC – best–supportive care; CI – confidence interval;
quality–adjusted life year; GEP – gene-expression profiling; SE – standard
* Adjusted for quality of life and discount rate for time preference.
† Differed significantly from 0; Po 0.05 (2-sided test).
z Immunohistochemistry use may change with use of GEP TOO.
y Cost of new surgeries.
** Additional blood tests or imaging procedures.97.5th percentiles of the ICER were $13,351 and $104,269, respec-
tively (Fig. 2; Table 2). A one-way sensitivity analysis showed
utility of GCRs, chemotherapy costs with GEP TOO testing, and
sample variance of quality-adjusted life-months to be the
key drivers of GEP TOO test’s cost-effectiveness (Fig. 3). Figure 4
shows the results of a two-way sensitivity analysis that we
performed by simultaneously varying the imputed effect of
non-GCR regimens on survival and the relative effect of GEP
TOO testing, the two variables for which no registry study or
literature data were available. The two-way sensitivity analysis
demonstrated that the ICER was more sensitive to the relative
effect of GEP TOO testing than to the imputed effect of non-GCR
regimens. The ICER increased by 39% (to $65,134) when the
relative effect of GEP TOO testing decreased by 50% and no effect
of non-GCR regimens was considered. The ICER decreased by
approximately 12% (to $41,095) when the relative effect of GEP
TOO testing increased by 50% and the effect of non-GCR regimens
on survival was assumed to be 100%. Eliminating the one case forGEP TOO testing Difference
ean SE Mean 95% CI
1.5% 8.4%
3.1% 15.0%
5.4% 23.4%
9.46 (1.33) 3.55 (3.17, 3.91)†
3.29 (0.96) 2.65 (1.50, 4.28)†
7,255 ($2,022) $6,829 ($2,686, $10,973)†
3,569 ($552) $191 ($1,099, $1,481)
1,190 ($61) 0
777 ($157) $699 ($1,096, $302)†
461 ($171) $461 ($126, $795)†
$32 ($10) $32 ($11, $52)†
$853 ($214) $853 ($1,272, $434)†
4,400 $4,400
6,831 ($2,238) $10,360 ($2,982, $19,192)†
USD) $46,858 ($13,351, $104,269)†
CT – chemotherapy; GCR – guideline-consistent regimen; QALY –
error; TOO – tissue of origin.
Fig. 2 – Scatterplot (A) and acceptability curve (B) from proba-
bilistic sensitivity analysis. QALYs, quality-adjusted life years.
Fig. 3 – One-way sensitivity analysis. ICER, incremental cost-ef
chemotherapy; GEP, gene-expression profiling; TOO, tissue of o
VA L U E I N H E A LT H 1 6 ( 2 0 1 3 ) 4 6 – 5 652which GCR/non-GCR classification differed among independent
raters decreased the ICER by 1%, to $46,248.Discussion
This study is the first to estimate the outcomes, costs, and cost-
effectiveness of a novel GEP test, GEP TOO, versus usual care
among patients with metastatic and poorly differentiated cancer.
Patients in this sample had characteristics similar to those of
patients enrolled in other studies who have had metastatic
cancer in which the primary origin remained uncertain despite
extensive clinical and pathological evaluation [8,15,16]. Our study
found that overall survival is likely to increase from 15.9 to 19.5
months with the use of GEP TOO testing. These survival esti-
mates are consistent with the mean patient survival (20 months)
from registry data for the patients in our study. We projected
average costs per patient to increase, largely owing to physician
plans to administer more GCRs, which are more costly than no
chemotherapy or carboplatin plus paclitaxel (combined, these
account for 54% of the pre-GEP TOO testing regimens). The test
saves some costs by increasing referrals to hospice care and
reducing the use of radiation therapy.
The duration and quality of patient survival increase sub-
stantially if a physician chooses a chemotherapy regimen that
appropriately targets the correct tumor type [5,7,8]. This study
showed that physicians ordered GCRs for an additional 1 in 4
patients after receiving GEP TOO test results, which is associated
with improvements in patient QALYs. Literature showed the
benefit of appropriate chemotherapy to differ substantially by
cancer type. This difference is likely due to the variability in
treatment advances made for these cancers. Sensitivity analyses
showed that the effect of imputing survival for non-GCRs was
minimal. The small number of cases for which survival had to be
imputed likely accounts for this result.
The findings from this study should be evaluated in light of
potential limitations. The study design for evaluating a new
technology should limit risks to internal and external validity. A
randomized controlled trial involving multiple centers that has afectiveness ratio; GCR, guideline-consistent regimen; CT,
rigin; IHC, immunohistochemistry.
Fig. 4 – Two-way sensitivity analysis of ICER, varying
relative effect of GEP TOO and imputed percent effect of
non-GCR regimens. 1Relative effect: 1 – observed effect of
GEP TOO on ICER is true causal effect; 0.5 – half the observed
changes in ICER are causally related to GEP TOO; 1.5 – one
and a half times the observed changes in ICER are causally
related to GEP TOO. ICER, incremental cost-effectiveness
ratio; GEP, gene-expression profiling; TOO, tissue of origin.
VA L U E I N H E A LT H 1 6 ( 2 0 1 3 ) 4 6 – 5 6 53sufficiently large sample size is the strongest design for limiting
risks to internal validity because it balances confounding vari-
ables among the comparator arms. For a number of pragmatic
reasons, randomized studies are exceedingly rare in metastatic
or poorly differentiated cancers that are more difficult to diag-
nose than other cancers. Funders, including government agen-
cies, are reluctant to sponsor randomized trials of such cancers
owing to the high costs associated with the extremely large
sample sizes needed to achieve statistically significant results
because of the heterogeneity in tumor and histological types
and in treatment options for each tumor. Moreover, the lower
incidence of some metastatic or poorly differentiated cancer
presentations (such as cervical, parotid gland, and urethral) than
that of other cancers (such as breast, lung, and colon), combined
with historical challenges of recruiting patients into randomized
trials in general, makes undertaking a randomized trial of GEP
TOO testing difficult. Our approach relied on an established
alternative, namely, an observational design that offers less
confidence that risks to internal validity have been minimized.
To address this concern, we varied the relative effect of GEP TOO
testing on end points between 50% and 150% of the effect
observed in the study. This approach offers the reader a trans-
parent and explicit way to assess the effect of potential threats to
the study’s internal validity.
Another potential limitation is our omission of some potential
effects on costs, such as potential savings from delaying costly
progression and use of second-line therapies, and on QOL, such as
reduced patient uncertainty about their diagnosis, increased
confidence in the value of the recommended therapies, and QOL
benefits from hospice referrals or radiation therapy. GEP TOO test
results likely increased the QOL by increasing patient certainty, as
indicated by physicians’ belief that GEP TOO test results helped
reduce patient anxiety about their diagnosis and the managementof their cancer. Studies have shown that patients express will-
ingness to pay for tests that reduce uncertainty in diagnosis even
if the information may not alter therapy or outcomes [104]. Our
omission of the effects of GEP TOO testing on these costs and QOL
factors likely biased the cost-per-QALY estimate against GEP TOO
testing. A longitudinal follow-up study would be useful for
revealing the effect of GEP TOO testing on cancer progression
and use of subsequent therapies and, thus, on costs and patient
QOL. As the use of GEP TOO testing increases, studies with larger
sample sizes will become possible. These studies will allow for a
better understanding of the test’s potential effects on radiation
therapy and surgery. Such studies would also allow the use of
statistical methods for causal inference [113].
GEP TOO testing will probably be used for a small proportion
(2%) of the more than 1.5 million people who are likely to be
diagnosed with cancer in 2012. A similar number of patients is
likely to be eligible for the treatment of metastatic prostate
cancer with the new drug sipuleucel-T (Provenge, Dendreon,
Seattle, WA), which is estimated to cost more than $90,000 for a
course of therapy to extend survival in the last year of life by
about 4 months [104,114]. The cost-effectiveness of the drug for
this indication is likely to far exceed $100,000 per QALY saved.
Historically, $50,000 has been used as the threshold for cost-
effectiveness; however, assessments of current cancer manage-
ment and dialysis strategies have shown more than $100,000 to
be a more contemporary threshold for the adoption of health
care technologies [115,116]. We found that the cost per QALY
gained with GEP TOO testing remained within both historical and
contemporary thresholds. The cost per QALY gained would
exceed $100,000 if the changes attributed to GEP TOO testing
were less than 25% of those observed in this study.
GEP TOO testing significantly altered clinical practice patterns.
We project that these changes increase overall survival and
QALYs for patients whose physicians order the test. The estimated
cost per QALY gained is less than $50,000, suggesting that GEP TOO
testing is a cost-effective supplement for cancer management in
patients with difficult-to-diagnose metastatic cancer.Acknowledgment
We acknowledge Leona Han for assisting in data collection.
Source of financial support: Pathwork Diagnostics, Inc., funded
this study.Supplemental Materials
Supplemental material accompanying this article can be found in
the online version as a hyperlink at http://dx.doi.org/10.1016/j.jval.
2010.10.016 or, if a hard copy of article, at http://www.valuein
healthjournal.com/issues (select volume, issue, and article).R E F E R E N C E S[1] Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010. CA Cancer J Clin
2010;60:277–300.
[2] Pavlidis N, Fizazi K. Carcinoma of unknown primary (CUP). Crit Rev
Oncol Hematol 2009;69:271–8.
[3] Botkin J, Teutsch S, Kaye C, et al. Outcomes of interest in evidence-
based evaluations of genetic tests. Genet Med 2010;12:228–35.
[4] Teutsch S, Bradley L, Palomaki G, et al. The Evaluation of Genomic
Applications in Practice and Prevention (EGAPP) initiative: methods of
the EGAPP Working Group. Genet Med 2009;11:3–14.
VA L U E I N H E A LT H 1 6 ( 2 0 1 3 ) 4 6 – 5 654[5] National Comprehensive Cancer Network. NCCN guidelines:
carcinoma of unknown primary. Available from: http://www.nccn.org/
professionals/physician_gls/f_guidelines.asp#occult. [Accessed
January 12, 2011].
[6] Pavlidis N, Briasoulis E, Hainsworth J, et al. Diagnostic and therapeutic
management of cancer of an unknown primary. Eur J Cancer
2003;39:1990–2005.
[7] Abbruzzese JL, Abbruzzese MC, Lenzi R, et al. Analysis of a diagnostic
strategy for patients with suspected tumors of unknown origin. J Clin
Oncol 1995;13:2094–103.
[8] Varadhachary GR, Talantov D, Raber MN, et al. Molecular profiling of
carcinoma of unknown primary and correlation with clinical
evaluation. J Clin Oncol 2008;26:4442–8.
[9] Bahrami A, Truong L, Ro J. Undifferentiated tumor: true identity by
immunohistochemistry. Arch Pathol Lab Med 2008;132:326–48.
[10] Brown R, Campagna L, Dunn J, et al. Immunohistochemical
identification of tumor markers in metastatic adenocarcinoma: a
diagnostic adjunct in the determination of primary site. Am J Clin
Pathol 1997;107:12–9.
[11] Goldstein N, Hewitt S, Taylor C, et al. Recommendations for improved
standardization of immunohistochemistry. Appl Immunohistochem
Mol Morphol 2007;15:124–33.
[12] Park S, Kim B, Kim J, et al. Panels of immunohistochemical markers
help determine primary sites of metastatic adenocarcinoma. Arch
Pathol Lab Med 2007;131:1561–7.
[13] Monzon F, Koen T. Diagnosis of metastatic neoplasms: molecular
approaches for identification of tissue of origin. Arch Pathol Lab Med
2010;134:216–24.
[14] Monzon FA, Dumur CI. Diagnosis of uncertain primary tumors with
the Pathwork tissue-of-origin test. Expert Rev Mol Diagn
2010;10:17–25.
[15] Monzon FA, Lyons-Weiler M, Buturovic LJ, et al. Multicenter validation
of a 1,550-gene expression profile for identification of tumor tissue of
origin. J Clin Oncol 2009;27:2503–8.
[16] Pillai R, Deeter R, Rigl CT, et al. Validation and reproducibility of a
microarray-based gene expression test for tumor identification in
formalin-fixed, paraffin-embedded specimens. J Mol Diagn
2011;13:48–56.
[17] Dumur CI, Fuller CE, Blevins TL, et al. Clinical verification of the
performance of the pathwork tissue of origin test: utility and
limitations. Am J Clin Pathol 2011;136:924–33.
[18] Nystrom SJ, Hornberger JC, Varadhachary GR, et al. Clinical utility of
gene-expression profiling for tumor-site origin in patients with
metastatic or poorly differentiated cancer: impact on diagnosis,
treatment, and survival. Oncotarget 2012;3:620–8.
[19] Carlson M, Herrin J, Du Q, et al. Impact of hospice disenrollment on
health care use and Medicare expenditures for patients with cancer.
J Clin Oncol 2010;28:4371–5.
[20] Minter R, Spengler K, Topping D, et al. Institutional validation of breast
cancer treatment guidelines. J Surg Res 2001;100:106–9.
[21] Neubauer M, Hoverman J, Kolodziej M, et al. Cost effectiveness of
evidence-based treatment guidelines for the treatment of non-small-
cell lung cancer in the community setting. J Oncol Pract 2010;6:12–8.
[22] UpToDate. Available from: http://www.uptodate.com/. [Accessed
March 11, 2011].
[23] Siegel J, Weinstein M, Russell L, et al. Recommendations for reporting
cost-effectiveness analyses. Panel on Cost-Effectiveness in Health and
Medicine. JAMA 1996;276:1339–41.
[24] Lipscomb W, Torrance G. Time preference. In: Gold M, Siegel J, Russell
L, eds. Cost-Effectiveness in Health and Medicine. New York: Oxford
University Press; 1996: Chap. 7.
[25] Tanum G. Treatment of relapsing anal carcinoma. Acta Oncol
1993;32:33–5.
[26] Redman BG, Smith DC, Flaherty L, et al. Phase II trial of paclitaxel and
carboplatin in the treatment of advanced urothelial carcinoma. J Clin
Oncol 1998;16:1844–8.
[27] Vaishampayan U. Systemic therapy of advanced urothelial cancer.
Curr Treat Options Oncol 2009;10:256–66.
[28] Xu N, Zhang XC, Xiong JP, et al. A phase II trial of gemcitabine plus
carboplatin in advanced transitional cell carcinoma of the urothelium.
BMC Cancer 2007;7:98.
[29] Bergh J, Jonsson PE, Glimelius B, et al. A systematic overview of
chemotherapy effects in breast cancer. Acta Oncol 2001;40:253–81.
[30] Fountzilas G, Kalofonos HP, Dafni U, et al. Paclitaxel and epirubicin
versus paclitaxel and carboplatin as first-line chemotherapy in
patients with advanced breast cancer: a phase III study conducted by
the Hellenic Cooperative Oncology Group. Ann Oncol 2004;15:1517–26.
[31] Howell A, Robertson JF, Abram P, et al. Comparison of fulvestrant
versus tamoxifen for the treatment of advanced breast cancer in
postmenopausal women previously untreated with endocrine
therapy: a multinational, double-blind, randomized trial. J Clin Oncol
2004;22:1605–13.[32] Katsumata N, Watanabe T, Minami H, et al. Phase III trial of doxorubicin
plus cyclophosphamide (AC), docetaxel, and alternating AC and
docetaxel as front-line chemotherapy for metastatic breast cancer: Japan
Clinical Oncology Group trial (JCOG9802). Ann Oncol 2009;20:1210–5.
[33] Marty M, Cognetti F, Maraninchi D, et al. Randomized phase II trial of
the efficacy and safety of trastuzumab combined with docetaxel in
patients with human epidermal growth factor receptor 2-positive
metastatic breast cancer administered as first-line treatment: the
M77001 study group. J Clin Oncol 2005;23:4265–74.
[34] Nabholtz JM, Falkson C, Campos D, et al. Docetaxel and doxorubicin
compared with doxorubicin and cyclophosphamide as first-line
chemotherapy for metastatic breast cancer: results of a randomized,
multicenter, phase III trial. J Clin Oncol 2003;21:968–75.
[35] Trent JC, Valero V, Booser DJ, et al. A phase I study of docetaxel plus
cyclophosphamide in solid tumors followed by a phase II study as
first-line therapy in metastatic breast cancer. Clin Cancer Res
2003;9:2426–34.
[36] Bonomi P, Blessing JA, Stehman FB, et al. Randomized trial of three
cisplatin dose schedules in squamous-cell carcinoma of the cervix: a
Gynecologic Oncology Group study. J Clin Oncol 1985;3:1079–85.
[37] Glimelius B, Hoffman K, Sjoden PO, et al. Chemotherapy improves
survival and quality of life in advanced pancreatic and biliary cancer.
Ann Oncol 1996;7:593–600.
[38] Knox JJ, Hedley D, Oza A, et al. Combining gemcitabine and
capecitabine in patients with advanced biliary cancer: a phase II trial. J
Clin Oncol 2005;23:2332–8.
[39] Valle J, Wasan H, Palmer DH, et al. Cisplatin plus gemcitabine versus
gemcitabine for biliary tract cancer. N Engl J Med 2010;362:1273–81.
[40] Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy
and cetuximab plus irinotecan in irinotecan-refractory metastatic
colorectal cancer. N Engl J Med 2004;351:337–45.
[41] Fuchs CS, Marshall J, Mitchell E, et al. Randomized, controlled trial of
irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line
treatment of metastatic colorectal cancer: results from the BICC-C
Study. J Clin Oncol 2007;25:4779–86.
[42] Moosmann N, von Weikersthal LF, Vehling-Kaiser U, et al. Cetuximab
plus capecitabine and irinotecan compared with cetuximab plus
capecitabine and oxaliplatin as first-line treatment for patients with
metastatic colorectal cancer: AIO KRK-0104—a randomized trial of the
German AIO CRC study group. J Clin Oncol 2011;29:1050–8.
[43] O’Dwyer PJ, Manola J, Valone FH, et al. Fluorouracil modulation in
colorectal cancer: lack of improvement with N-phosphonoacetyl-L-
aspartic acid or oral leucovorin or interferon, but enhanced
therapeutic index with weekly 24-hour infusion schedule—an Eastern
Cooperative Oncology Group/Cancer and Leukemia Group B Study. J
Clin Oncol 2001;19:2413–21.
[44] Saif MW. Does OPTIMOXstrategy (‘‘stop-and-go’’ approach) also work
in treatment of pancreatic cancer with oxaliplatin-based regimens?
JOP 2008;9:658–63.
[45] Saltz LB, Clarke S, Diaz-Rubio E, et al. Bevacizumab in combination
with oxaliplatin-based chemotherapy as first-line therapy in
metastatic colorectal cancer: a randomized phase III study. J Clin
Oncol 2008;26:2013–9.
[46] Scheithauer W, Rosen H, Kornek GV, et al. Randomised comparison of
combination chemotherapy plus supportive care with supportive care
alone in patients with metastatic colorectal cancer. BMJ
1993;306:752–5.
[47] Tebbutt NC, Wilson K, Gebski VJ, et al. Capecitabine, bevacizumab,
and mitomycin in first-line treatment of metastatic colorectal cancer:
results of the Australasian Gastrointestinal Trials Group Randomized
Phase III MAX Study. J Clin Oncol 28:3191–3198.
[48] Van Cutsem E, Rivera F, Berry S, et al. Safety and efficacy of first-line
bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in
metastatic colorectal cancer: the BEAT study. Ann Oncol
2009;20:1842–7.
[49] Ries L, Melbert D, Krapcho M, et al. SEER Cancer Statistics Review,
1975–2005. Bethesda, MD: National Cancer Institute, 2008.
[50] Hitchins RN, Newlands ES, Smith DB, et al. Long-term outcome in
patients with germ cell tumours treated with POMB/ACE
chemotherapy: comparison of commonly used classification systems
of good and poor prognosis. Br J Cancer 1989;59:236–42.
[51] Cunningham D, Starling N, Rao S, et al. Capecitabine and oxaliplatin
for advanced esophagogastric cancer. N Engl J Med 2008;358:36–46.
[52] El-Rayes BF, Shields A, Zalupski M, et al. A phase II study of carboplatin
and paclitaxel in esophageal cancer. Ann Oncol 2004;15:960–5.
[53] Pyrhonen S, Kuitunen T, Nyandoto P, et al. Randomised comparison of
fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus
supportive care with supportive care alone in patients with non-
resectable gastric cancer. Br J Cancer 1995;71:587–91.
[54] Clark JI, Hofmeister C, Choudhury A, et al. Phase II evaluation of
paclitaxel in combination with carboplatin in advanced head and
neck carcinoma. Cancer 2001;92:2334–40.
VA L U E I N H E A LT H 1 6 ( 2 0 1 3 ) 4 6 – 5 6 55[55] Kowalski LP, Carvalho AL. Natural history of untreated head and neck
cancer. Eur J Cancer 2000;36:1032–7.
[56] Vermorken JB, Trigo J, Hitt R, et al. Open-label, uncontrolled,
multicenter phase II study to evaluate the efficacy and toxicity of
cetuximab as a single agent in patients with recurrent and/or
metastatic squamous cell carcinoma of the head and neck who failed
to respond to platinum-based therapy. J Clin Oncol 2007;25:2171–7.
[57] Buti S, Lazzarelli S, Chiesa MD, et al. Dose-finding trial of a combined
regimen with bevacizumab, immunotherapy, and chemotherapy in
patients with metastatic renal cell cancer: an Italian Oncology Group
for Clinical Research (GOIRC) study. J Immunother 2010;33:735–41.
[58] Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa,
or both for advanced renal-cell carcinoma. N Engl J Med
2007;356:2271–81.
[59] Motzer RJ, Hutson TE, Tomczak P, et al. Overall survival and updated
results for sunitinib compared with interferon alfa in patients with
metastatic renal cell carcinoma. J Clin Oncol 2009;27:3584–90.
[60] Paz-Ares L, del Muro JG, Grande E, et al. A cost-effectiveness analysis
of sunitinib in patients with metastatic renal cell carcinoma
intolerant to or experiencing disease progression on immunotherapy:
perspective of the Spanish National Health System. J Clin Pharm Ther
2010;35:429–38.
[61] Abou-Alfa GK, Schwartz L, Ricci S, et al. Phase II study of sorafenib in
patients with advanced hepatocellular carcinoma. J Clin Oncol
2006;24:4293–300.
[62] Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in
patients in the Asia-Pacific region with advanced hepatocellular
carcinoma: a phase III randomised, double-blind, placebo-controlled
trial. Lancet Oncol 2009;10:25–34.
[63] Qin S, Bai Y, Ye S, et al. ASCO Annual Meeting Oral Abstract Session,
Gastrointestinal (Noncolorectal) Cancer. J Clin Oncol 2010; 28:15s
(suppl; abstr 4008).
[64] Ulrich-Pur H, Kornek GV, Fiebiger W, et al. Treatment of advanced
hepatocellular carcinoma with biweekly high-dose gemcitabine.
Oncology 2001;60:313–5.
[65] Belani CP, Lee JS, Socinski MA, et al. Randomized phase III trial
comparing cisplatin-etoposide to carboplatin-paclitaxel in advanced
or metastatic non-small cell lung cancer. Ann Oncol 2005;16:1069–75.
[66] Cellerino R, Tummarello D, Guidi F, et al. A randomized trial of
alternating chemotherapy versus best supportive care in advanced
non-small-cell lung cancer. J Clin Oncol 1991;9:1453–61.
[67] Johnson DH, Fehrenbacher L, Novotny WF, et al. Randomized phase II
trial comparing bevacizumab plus carboplatin and paclitaxel with
carboplatin and paclitaxel alone in previously untreated locally
advanced or metastatic non-small-cell lung cancer. J Clin Oncol
2004;22:2184–91.
[68] Paccagnella A, Oniga F, Bearz A, et al. Adding gemcitabine to
paclitaxel/carboplatin combination increases survival in advanced
non-small-cell lung cancer: results of a phase II–III study. J Clin Oncol
2006;24:681–7.
[69] Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing
cisplatin plus gemcitabine with cisplatin plus pemetrexed in
chemotherapy-naive patients with advanced-stage non-small-cell
lung cancer. J Clin Oncol 2008;26:3543–51.
[70] Sederholm C, Hillerdal G, Lamberg K, et al. Phase III trial of
gemcitabine plus carboplatin versus single-agent gemcitabine in the
treatment of locally advanced or metastatic non-small-cell lung
cancer: the Swedish Lung Cancer Study Group. J Clin Oncol
2005;23:8380–8.
[71] National Institutes of Health Clinical Trials Database. Temozolomide
Versus Dacarbazine in Stage IV Metastatic Melanoma. Study
P03267AM2. 2010.
[72] Smith FO, Downey SG, Klapper JA, et al. Treatment of metastatic
melanoma using interleukin-2 alone or in conjunction with vaccines.
Clin Cancer Res 2008;14:5610–8.
[73] Case AS, Rocconi RP, Partridge EE, et al. A cost-effectiveness analysis
of chemotherapy for patients with recurrent platinum-sensitive
epithelial ovarian cancer. Gynecol Oncol 2007;105:223–7.
[74] Neijt JP, Engelholm SA, Tuxen MK, et al. Exploratory phase III study of
paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced
ovarian cancer. J Clin Oncol 2000;18:3084–92.
[75] Pectasides D, Pectasides M, Farmakis D, et al. Oxaliplatin plus high-
dose leucovorin and 5-fluorouracil (FOLFOX 4) in platinum-resistant
and taxane-pretreated ovarian cancer: a phase II study. Gynecol Oncol
2004;95:165–72.
[76] Slevin ML, Harvey VJ, Osborne RJ, et al. A phase II study of tamoxifen
in ovarian cancer. Eur J Cancer Clin Oncol 1986;22:309–12.
[77] Andersen JR, Friis-Moller A, Hancke S, et al. A controlled trial of
combination chemotherapy with 5-FU and BCNU in pancreatic cancer.
Scand J Gastroenterol 1981;16:973–5.
[78] Brentjens R, Saltz L. Islet cell tumors of the pancreas: the medical
oncologist’s perspective. Surg Clin North Am 2001;81:527–42.[79] Cartwright TH, Cohn A, Varkey JA, et al. Phase II study of oral
capecitabine in patients with advanced or metastatic pancreatic
cancer. J Clin Oncol 2002;20:160–4.
[80] Colucci G, Labianca R, Di Costanzo F, et al. Randomized phase III trial
of gemcitabine plus cisplatin compared with single-agent gemcitabine
as first-line treatment of patients with advanced pancreatic cancer:
the GIP-1 study. J Clin Oncol 2010;28:1645–51.
[81] Cullinan SA, Moertel CG, Fleming TR, et al. A comparison of three
chemotherapeutic regimens in the treatment of advanced pancreatic
and gastric carcinoma: fluorouracil vs fluorouracil and doxorubicin vs
fluorouracil, doxorubicin, and mitomycin. JAMA 1985;253:2061–7.
[82] Louvet C, Labianca R, Hammel P, et al. Gemcitabine in combination
with oxaliplatin compared with gemcitabine alone in locally advanced
or metastatic pancreatic cancer: results of a GERCOR and GISCAD
phase III trial. J Clin Oncol 2005;23:3509–16.
[83] Rougier P, Adenis A, Ducreux M, et al. A phase II study: docetaxel as
first-line chemotherapy for advanced pancreatic adenocarcinoma. Eur
J Cancer 2000;36:1016–25.
[84] Whitehead RP, Jacobson J, Brown TD, et al. Phase II trial of paclitaxel
and granulocyte colony-stimulating factor in patients with pancreatic
carcinoma: a Southwest Oncology Group study. J Clin Oncol
1997;15:2414–9.
[85] Chamberlain RS, Canes D, Brown KT, et al. Hepatic neuroendocrine
metastases: does intervention alter outcomes? J Am Coll Surg
2000;190:432–45.
[86] Airoldi M, Pedani F, Succo G, et al. Phase II randomized trial comparing
vinorelbine versus vinorelbine plus cisplatin in patients with
recurrent salivary gland malignancies. Cancer 2001;91:541–7.
[87] Creagan ET, Woods JE, Rubin J, et al. Cisplatin-based chemotherapy for
neoplasms arising from salivary glands and contiguous structures in
the head and neck. Cancer 1988;62:2313–9.
[88] Mita MM, Tolcher AW. The role of mTOR inhibitors for treatment of
sarcomas. Curr Oncol Rep 2007;9:316–22.
[89] Penel N, Bui BN, Bay JO, et al. Phase II trial of weekly paclitaxel for
unresectable angiosarcoma: the ANGIOTAX study. J Clin Oncol
2008;26:5269–74.
[90] Santoro A, Tursz T, Mouridsen H, et al. Doxorubicin versus CYVADIC
versus doxorubicin plus ifosfamide in first-line treatment of advanced
soft tissue sarcomas: a randomized study of the European
Organization for Research and Treatment of Cancer Soft Tissue and
Bone Sarcoma Group. J Clin Oncol 1995;13:1537–45.
[91] Soini EJ, Garcia San Andres B, Joensuu T. Trabectedin in the treatment
of metastatic soft tissue sarcoma: cost-effectiveness, cost-utility and
value of information. Ann Oncol 2011;22:215–23.
[92] Culine S, Fabbro M, Ychou M, et al. Alternative bimonthly cycles of
doxorubicin, cyclophosphamide, and etoposide, cisplatin with
hematopoietic growth factor support in patients with carcinoma of
unknown primary site. Cancer 2002;94:840–6.
[93] Greco FA, Erland JB, Morrissey LH, et al. Carcinoma of unknown
primary site: phase II trials with docetaxel plus cisplatin or
carboplatin. Ann Oncol 2000;11:211–5.
[94] Greco FA, Pavlidis N. Treatment for patients with unknown primary
carcinoma and unfavorable prognostic factors. Semin Oncol
2009;36:65–74.
[95] Greco FA, Burris HA III, Erland JB, et al. Carcinoma of unknown
primary site. Cancer 2000;89:2655–60.
[96] Kouno T, Ando M, Yonemori K, et al. Weekly paclitaxel and carboplatin
against advanced transitional cell cancer after failure of a platinum-
based regimen. Eur Urol 2007;52:1115–22.
[97] Eng TY, Naguib M, Galang T, et al. Retrospective study of the treatment
of urethral cancer. Am J Clin Oncol 2003;26:558–62.
[98] Babaian RJ, Johnson DE, Llamas L, et al. Metastases from transitional
cell carcinoma of urinary bladder. Urology 1980;16:142–4.
[99] von der Maase H, Hansen SW, Roberts JT, et al. Gemcitabine and
cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin
in advanced or metastatic bladder cancer: results of a large,
randomized, multinational, multicenter, phase III study. J Clin Oncol
2000;18:3068–77.
[100] van Wijk FH, Lhomme C, Bolis G, et al. Phase II study of carboplatin in
patients with advanced or recurrent endometrial carcinoma: a trial of
the EORTC Gynaecological Cancer Group. Eur J Cancer 2003;39:78–85.
[101] Tufts Medical Centers. CEA Registry. Available from: https://research.
tufts-nemc.org/cear4/Home.aspx. [Accessed July 1, 2011].
[102] US National Library of Medicines. PubMed. Available from: http://
www.ncbi.nlm.nih.gov/pubmed. [Accessed July 1, 2011].
[103] Chabot I, Rocchi A. How do cost-effectiveness analyses inform
reimbursement decisions for oncology medicines in Canada? The
example of sunitinib for first-line treatment of metastatic renal cell
carcinoma. Value Health 2010;13:837–45.
[104] Neumann PJ, Cohen JT, Hammitt JK, et al. Willingness-to-pay for
predictive tests with no immediate treatment implications: a survey
of US residents. Health Econ 2012;21:238–51.
VA L U E I N H E A LT H 1 6 ( 2 0 1 3 ) 4 6 – 5 656[105] Centers for Medicare & Medicaid Services. Centers for Medicare &
Medicaid Services (CMS) physician fee schedule. Available from:
http://www.cms.gov/apps/physician-fee-schedule/search/
search-criteria.aspx. [Accessed March 11, 2011].
[106] Centers for Medicare & Medicaid Services. FY 2011 final rule tables.
Available from: http://www.cms.gov/acuteinpatientpps/ipps2011/
itemdetail.asp?itemid=CMS1237948. [Accessed March 11, 2011].
[107] Centers for Medicare & Medicaid Servicess. Physician fee schedule
search. Available from: https://www.cms.gov/apps/
physician-fee-schedule/search/search-criteria.aspx. [Accessed
November 15, 2011].
[108] Campbell D, Lynn J, Louis T, et al. Medicare program expenditures
associated with hospice use. Ann Intern Med 2004;140:269–77.
[109] Gade G, Venohr I, Conner D, et al. Impact of an inpatient palliative
care team: a randomized control trial. J Palliat Med 2008;11:180–90.
[110] Taylor DJ. The effect of hospice on Medicare and informal care costs:
the U.S. Experience. J Pain Symptom Manage 2009;38:110–4.
[111] Briggs A, Claxton K, Sculpher M. Decision Modelling for Health
Economic Evaluation. Oxford: Oxford University Press, 2006.[112] Briggs A, Fenn P. Confidence intervals or surfaces? Uncertainty on the
cost-effectiveness plane. Health Econ 1998;7:723–40.
[113] Johnson ML, Crown W, Martin BC, et al. Good research practices for
comparative effectiveness research: analytic methods to improve
causal inference from nonrandomized studies of treatment effects
using secondary data sources. The ISPOR Good Research Practices for
Retrospective Database Analysis Task Force Report—Part III. Value
Health 2009;12:1062–73.
[114] Small E, Schellhammer P, Higano C, et al. Placebo-controlled phase III
trial of immunologic therapy with sipuleucel-T (APC8015) in patients
with metastatic, asymptomatic hormone refractory prostate cancer.
J Clin Oncol 2006;24:3089–94.
[115] Lee CP, Chertow GM, Zenios SA. An empiric estimate of the value of
life: updating the renal dialysis cost-effectiveness standard. Value
Health 2009;12:80–7.
[116] Greenberg D, Earle C, Fang CH, et al. When is cancer care cost-
effective? A systematic overview of cost-utility analyses in oncology. J
Natl Cancer Inst 2010;102:82–8.
